Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CRT, ArcticDx combine in cancer risk tech pact

This article was originally published in Clinica

Executive Summary

London, UK-based oncology specialist Cancer Research Technology (CRT) has teamed up with Canadian molecular testing firm ArcticDx in a licensing agreement for the latter’s Colo Risk test for colorectal cancer. The non-exclusive agreement will see results from genome-wide Cancer Research UK-funded studies integrated into ArcticDx’s risk assessment technology. The aim is to help healthcare professionals assess patients who might be at a higher risk of developing bowel cancer, so they may receive specific individual treatment. Toronto, Ontario-based ArcticDx will make an upfront payment to CRT, which will also receive royalties form sales of the Colo Risk test.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT042184

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel